Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2025
Date Filed: May 23, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise reporting a change in substantial holding, this Form 6-K does not contain financial statements or performance metrics.
Material Changes
The primary material event disclosed in this filing is a Change in substantial holding (Exhibit 99.1). No other operational or financial changes are detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily to incorporate the change in substantial holding into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 to identify the specific shareholder and the magnitude of the change in substantial holding.
- Verify the impact of this holding change on the company's capital structure and voting control.
- Check the referenced Registration Statements (Form S-8 and Form F-3) for updated prospectus supplements if applicable.
- Confirm the company's continued status as a development stage enterprise and its current cash runway, as no financial data is present in this specific filing.